Orchestra BioMed Holdings (OBIO) Enterprise Value (2020 - 2026)
Orchestra BioMed Holdings (OBIO) posted quarterly Enterprise Value of -$84.6 million for Q1 2026, down 69.65% year-over-year from -$278.8 million in Q1 2025, and up 42.28% quarter-over-quarter from -$146.6 million in Q4 2025.
Orchestra BioMed Holdings (OBIO) Enterprise Value (2020 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has reported Enterprise Value for 7 consecutive years, with -$84.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 69.65% year-over-year to -$84.6 million; the TTM figure through Mar 2026 stood at -$84.6 million (down 69.65% YoY), while the FY2025 annual figure was -$146.6 million, down 44.67% from the prior year.
- Enterprise Value improved to -$84.6 million in Q1 2026 per OBIO's latest filing, from -$146.6 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$735217.0 in Q3 2022 and bottomed at -$215.9 million in Q2 2023.
- Historically, Enterprise Value has averaged -$73.4 million across 5 years, with a median of -$84.6 million in 2026.
- Annual changes were most pronounced in 2023 — Enterprise Value plunged 16418.84% — and 2024, when it surged 81.64%.
- Orchestra BioMed Holdings' Enterprise Value stood at -$19.9 million in 2022, then slumped by 340.5% to -$87.5 million in 2023, then retreated by 15.79% to -$101.4 million in 2024, then sank by 44.67% to -$146.6 million in 2025, then soared by 42.28% to -$84.6 million in 2026.
- Business Quant data shows OBIO's Enterprise Value at -$84.6 million in Q1 2026, -$146.6 million in Q4 2025, and -$95.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Orchestra BioMed Holdings | 265.06 Mn | 80.63 Mn | 63,000.00 | -184.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -184.43 Mn |
| Mar 31, 2026 | -84.63 Mn |
| Dec 31, 2025 | -146.63 Mn |
| Sep 30, 2025 | -95.82 Mn |
| Jun 30, 2025 | -33.92 Mn |
| Mar 31, 2025 | -49.88 Mn |
| Dec 31, 2024 | -101.35 Mn |
| Sep 30, 2024 | -95.87 Mn |
| Jun 30, 2024 | -53.93 Mn |
| Mar 31, 2024 | -23.35 Mn |
| Dec 31, 2023 | -87.53 Mn |
| Sep 30, 2023 | -108.49 Mn |
| Jun 30, 2023 | -215.85 Mn |
| Mar 31, 2023 | -127.13 Mn |
| Dec 31, 2022 | -19.87 Mn |
| Sep 30, 2022 | -735,217.00 |
| Jun 30, 2022 | -1.31 Mn |
| Mar 31, 2022 | -1.42 Mn |
| Dec 31, 2021 | -1.75 Mn |
| Sep 30, 2021 | -1.78 Mn |